Monash University drug discovery researchers have found that a natural fat molecule called ‘lipoxin A4’ (LXA4) could significantly reduce inflammation and improve function for diabetic hearts.

Drug discovery researchers have found that a natural fat molecule called 'lipoxin A4' (LXA4) could significantly reduce inflammation and improve function for diabetic hearts.

Using a gene-screening method they created, Stanford Medicine researchers may have discovered why an effective chemotherapy ...

The preclinical study, published in Cardiovascular Diabetology, found LXA4, which is known for its "calming agent" action in ...

Weight-Loss Drug Reduces Risk of Early Death for Patients With Heart Failure, Trial Finds Nov ... recently that heart muscle cells grown from induced pluripotent stem cells can integrate into ...

Using a gene-screening method, Stanford Medicine researchers have uncovered why chemotherapy can damage heart cells and have ...

A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows. The test of tirzepatide, brand named Zepbound ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study. In the ...

“This class of drug continues to show benefits far beyond weight loss,” he said. “It could become a key treatment for patients with obesity-related heart failure and preserved heart function.

A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows. The test of tirzepatide, brand named Zepbound, included 731 ...

"By showing that entacapone induces iron deficiency, we have uncovered a new mechanism of drug-induced gut dysbiosis ... that often accompany Parkinson's disease treatment.